19 FEBRUARY 2025

EQUITY RESEARCH – RESULTS FLASH

PRARAM 9 HOSPITAL THAILAND / HEALTH CARE SERVICES



4Q24 results at first glance

กำไร 4Q24 โต 10% y-y เป็น 207 ลบ. ใกล้เคียงกับที่เราคาด

Highlights

- PR9 รายงานกำไร 4Q24 อยู่ที่ 207 ลบ. (+10% y-y, -1% q-q) ใกล้เคียงกับที่เราคาด
- ในไตรมาสนี้ PR9 มีรายการลดภาษีได้สุทธิ 18 ลบ. (จากการบริจาครถ X-ray มูลค่า 18 ลบ. ซึ่งใช้หักภาษีได้ 36 ลบ.) ดังนั้นกำไรปกติหลังหักประโยชน์ทางภาษีจึงลดลง 9% qq เป็น 189 ลบ. (เทียบกับ 208 ลบ. ใน 3Q24)
- แม้ว่ารายได้จะสูงขึ้น 2% q-q ไปทำสถิติสูงสุดใหม่ ตลาดอาจจะผิดหวังกับกำไรอยู่ เล็กน้อยเนื่องจากมีรายการพิเศษหลายรายการในค่าใช้จ่ายการขายและบริหาร ประกอบด้วยรายการด้อยค่าของสินทรัพย์ 6 ลบ. ค่าซ่อมบำรุงเพิ่มเติม 3-4 ลบ. และการ ปรับดันทุนปลายปี 8-10 ลบ. เมื่อหักรายการพิเศษดังกล่าวเราคาดกำไรปกติอยู่ที่ 203-205 ลบ.
- รายได้สูงขึ้น 7% y-y โดยได้ปัจจัยผลักดันจากรายได้ผู้ป่วยต่างชาติ (+51% y-y) เป็น หลัก ในขณะที่รายได้ผู้ป่วยชาวไทยทรงตัว y-y จากฐานที่สูงและการชะลอตัวทาง เศรษฐกิจ
- สัดส่วนรายได้จากผู้ป่วยชาวไทยคิดเป็น 80% ในขณะที่รายได้ผู้ป่วยต่างชาติคิดเป็น
 20% สูงที่สุดเมื่อเทียบกับ 15-18% ก่อนหน้า
- ค่าใช้จ่ายการขายและบริหารเพิ่มขึ้น 15% y-y และ 13% q-q ดังได้กล่าวไว้แล้วเบื้องต้น ในขณะที่ดันทุนขายสูงขึ้น 8% y-y ซึ่งทำให้ EBITDA margin ลดลงเหลือ 23% ใน 4Q24 (เทียบกับ 25% ใน 4Q23) เมื่อหักรายการพิเศษต่าง ๆ EBITDA margin น่าจะอยู่ ที่ 25%
- ในปี 2024 กำไรปกติกระโดดเพิ่ม 28% y-y เป็น 713 ลบ. ใกล้เคียงกับที่เราคาด

Outlook and valuation

- เราเชื่อว่าราคาหุ้นที่ลดลงในปัจจุบันและความกังวลเกี่ยวกับค่าใช้จ่ายการขายและบริหาร ที่สูงขึ้นใน 4Q24 เป็นโอกาสในการซื้อเนื่องจากเราคาดว่ากำไรจะโตดีต่อเนื่อง y-y ใน 1Q25 โดยมีปัจจัยผลักดันจากรายได้ผู้ป่วยต่างชาติเป็นหลัก
- PR9 ประกาศจ่ายเงินปันผลสำหรับผลประกอบการในรอบ 2H25 อยู่ที่ 0.25 บาท/หุ้น (เงินปันผลระหว่างกาลรอบ 1H25 อยู่ที่ 0.15 บาท/หุ้น) คิดเป็นผลตอบแทนในรูปเงินปัน ผลอยู่ที่ 2%
- PR9 มีการซื้อขายโดยมี Valuation อยู่ในระดับที่น่าสนใจที่ 21x 2025E P/E พร้อม โอกาสที่จะได้ Upside จากรายได้ผู้ป่วยต่างชาติ

	UNCHANGED
RICE	THB30.00
	THB22.10

UP/DOWNSIDE	+35.7%
PRIOR TP	THB30.00
CHANGE IN TP	UNCHANGED
TP vs CONSENSUS	+1.3%

INANS

KEY STOCK DATA

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	4,635	5,068	5,481	5,872
Net profit	713	816	905	1,002
EPS (THB)	0.91	1.04	1.15	1.27
vs Consensus (%)	-	13.9	11.1	10.1
EBITDA	1,114	1,271	1,427	1,562
Recurring net profit	713	816	905	1,002
Core EPS (THB)	0.91	1.04	1.15	1.27
Chg. In EPS est. (%)	nm	0.0	0.0	nm
EPS growth (%)	27.8	14.5	10.9	10.7
Core P/E (x)	24.4	21.3	19.2	17.3
Dividend yield (%)	1.8	2.3	2.6	2.9
EV/EBITDA (x)	13.6	11.8	10.2	8.9
Price/book (x)	3.2	2.9	2.7	2.5
Net debt/Equity (%)	(41.2)	(40.4)	(44.2)	(48.7)
ROE (%)	13.6	14.3	14.6	14.9

TARGET P

CLOSE



Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA

Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

บทวิเคราะห์ฉบับนี้แปลมาจากตันฉบับภาษาอังกฤษ ที่ออกรายงานเมื่อวันที่ 19 กุมภาพันธ์ 2025

Exhibit 1: PR9 – 4Q24 results summary

FY ending Dec	4Q23	1Q24	2Q24	3Q24	4Q24	Cha	nge	2024	2025E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	1,175	1,071	1,084	1,226	1,255	2	7	4,635	5,068	9
COGS (incl depreciation)	(761)	(715)	(733)	(781)	(817)	5	7	(3,045)	(3,287)	8
Gross profit	414	356	350	445	439	(1)	6	1,590	1,781	12
SG&A	(209)	(182)	(204)	(212)	(240)	13	15	(837)	(884)	6
Operating profit	205	175	146	233	198	(15)	(3)	753	897	19
Net other income	16	10	14	10	21	106	29	55	57	3
Interest income	12	13	12	15	15	1	27	55	45	
Interest expenses	(0)	(0)	(0)	(0)	(0)			(0)	(1)	n/a
Pretax profit	233	197	173	258	234	(9)	1	862	998	16
Income tax	(45)	(38)	(34)	(50)	(28)	(44)	(38)	(149)	(182)	22
Core profit	188	159	139	208	207	(1)	10	713	816	14
Extraordinaries, GW & FX										
Reported net profit	188	159	139	208	207	(1)	10	713	816	14
Outstanding shares (m)	786	786	786	786	786	0	0	786	786	0
Pre-ex EPS (THB)	0.24	0.20	0.18	0.26	0.26	(1)	10	0.91	1.04	14
EPS (THB)	0.24	0.20	0.18	0.26	0.26	(1)	10	0.91	1.04	14
COGS excl. depreciation	(686)	(640)	(658)	(703)	(739)	5	8	(2,739)	(2,970)	8
Depreciation	(75)	(75)	(76)	(78)	(78)	1	4	(306)	(318)	4
EBITDA	297	259	236	321	298	(7)	0	1,114	1,271	14
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	35	33	32	36	35	(1)	(0)	34	35	1
SG&A/Revenue	18	17	19	17	19	2	1	18	17	(1)
EBITDA margin	25	24	22	26	23	(3)	(2)	24	25	1
Net profit margin	16	15	13	17	16	(1)	0	15	16	1
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	3	13	10	11	-					
OPD volume growth y-y	4	9	4	5	-					
OPD revenue per head growth y-y	(1)	4	6	6	-					
IPD revenue growth y-y	12	11	5	21	-					
IPD volume growth y-y	13	15	(4)	7	-					
IPD revenue per head growth y-y	(1)	(4)	10	13	-					
Thai patient revenue growth y-y	6	10	5	11	(0)					
Inter patient revenue growth y-y	9	25	24	42	51					

Sources: PR9; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Revenue	4,202	4,635	5,068	5,481	5,872
Cost of goods sold	(2,820)	(3,045)	(3,287)	(3,528)	(3,759)
Gross profit	1,382	1,590	1,781	1,954	2,112
Other operating income	51	55	57	59	60
Operating costs	(774)	(837)	(884)	(929)	(977)
Operating EBITDA	958	1,114	1,271	1,427	1,562
Depreciation	(299)	(306)	(318)	(344)	(366)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	659	808	953	1,084	1,196
Net financing costs	30	54	44	47	56
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	689	862	998	1,131	1,252
Tax	(131)	(149)	(182)	(226)	(250)
Profit after tax	558	713	816	905	1,002
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	_	-
Reported net profit	558	713	816	905	1,002
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	558	713	816	905	1,002
Per share (THB)					
Recurring EPS *	0.71	0.91	1.04	1.15	1.27
Reported EPS	0.71	0.91	1.04	1.15	1.27
DPS	0.30	0.40	0.52	0.58	0.64
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth					
Revenue (%)	2.3	10.3	9.3	8.1	7.1
Operating EBITDA (%)	(3.4)	16.3	14.1	12.3	9.4
Operating EBIT (%)	(4.7)	22.6	18.0	13.7	10.3
Recurring EPS (%)	(1.7)	27.8	14.5	10.9	10.7
Reported EPS (%)	(1.7)	27.8	14.5	10.9	10.7
Operating performance	()	2110	1 110	1010	
Gross margin inc. depreciation (%)	32.9	34.3	35.1	35.6	36.0
Gross margin exc. depreciation (%)	40.0	40.9	41.4	41.9	42.2
Operating EBITDA margin (%)	22.8	24.0	25.1	26.0	26.6
Operating EBIT margin (%)	15.7	17.4	18.8	19.8	20.0
Net margin (%)	13.3	15.4	16.1	16.5	17.1
Effective tax rate (%)	19.0	17.3	18.2	20.0	20.0
Dividend payout on recurring profit (%)	42.3	44.1	50.0	50.0	20.0 50.0
Interest cover (X)	(22.3)	(14.9)	(21.6)	(22.9)	(21.2)
Inventory days	7.2	7.0	7.3	7.3	(21.2)
Debtor days	23.1	24.9	26.7	28.7	7.3 30.8
Creditor days	73.9	24.9 77.9	82.9	83.3	30.8 87.5
Operating ROIC (%)	17.6	22.2	25.0	26.2	28.7
ROIC (%)	17.6				28.7 25.2
		19.7 13.6	21.8 14.3	23.0	25.2 14.9
ROE (%)	11.4	13.6		14.6	
ROA (%) * Pre-exceptional, pre-goodwill and fully diluted	9.3	10.9	11.7	12.0	12.2
		2024	20255	20205	2027E
Revenue by Division (THB m)	2023	2024	2025E	2026E	2027E
OPD patient revenue	2,491	2,731	2,998	3,243	3,474
IPD patient revenue	1,711	1,904	2,070	2,239	2,398

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
ecurring net profit	558	713	816	905	1,002
epreciation	299	306	318	344	366
ssociates & minorities	-	-	-	-	
ther non-cash items	10	(6)	0	0	C
change in working capital	(23)	63	1	(8)	58
Cash flow from operations	844	1,076	1,135	1,241	1,426
Capex - maintenance	(326)	(251)	(659)	(388)	(415
Capex - new investment	-	-	-	-	
let acquisitions & disposals	(100)	(128)	0	0	(
Other investments (net)	-	-	-	-	(445
Cash flow from investing	(426)	(379)	(659)	(388)	(415)
Dividends paid	(234)	(351)	(315)	(408)	(452)
Equity finance	0	0	0	0	0
Debt finance	1 0	(4)	0 0	0 0	(
Other financing cash flows		0			
Cash flow from financing	(233)	(355)	(315)	(408)	(452)
Ion-recurring cash flows	- 0	- 0	-	- 0	(
Dther adjustments let other adjustments	0	0	0	0	
Aovement in cash	184	341	161	445	558
ree cash flow to firm (FCFF)	418.17	697.32	476.45	445 853.50	1,011.24
ree cash flow to equity (FCFE)	418.73	692.74	475.75	852.80	1,011.24
		552.14	-10.10	552.00	1,010.34
er share (THB)					
CFF per share	0.53	0.89	0.61	1.09	1.29
CFE per share	0.53	0.88	0.61	1.08	1.29
Recurring cash flow per share	1.10	1.29	1.44	1.59	1.74
alance Sheet (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
angible fixed assets (gross)	5,898	5,992	6,651	7,039	7,454
ess: Accumulated depreciation	(2,556)	(2,705)	(3,022)	(3,366)	(3,732)
angible fixed assets (net)	3,343	3,288	3,629	3,673	3,722
ntangible fixed assets (net)	0	0	0	0	(
ong-term financial assets	-	-	-	-	0.00
nvest. in associates & subsidiaries	254	382	382	382	382
Cash & equivalents	1,901	2,243	2,404	2,849	3,407
VC receivable	290	343	400	462	529
nventories	48	57	62	66	70
Other current assets	12	15	16 2,882	18	19 4,02 6
Current assets Dther assets	2,251 62	2,658 72	2,002 72	3,395 72	4,020
otal assets	5,910	6,399	6,965	7,522	8,202
Common equity	5,080	5,439	5,940	6,437	6,986
Ainorities etc.	0	0	0 0	0,437	0,960
otal shareholders' equity	5,080	5,439	5,940	6,437	6,986
ong term debt	3,000 9	5	5	5	0,500
Other long-term liabilities	195	202	202	202	202
.ong-term liabilities	204	202 207	202 207	202 207	202 207
VC payable	522	647	702	752	874
Short term debt	0	047	0	0	(
Other current liabilities	105	106	116	126	135
Current liabilities	626	754	818	878	1,009
otal liabilities and shareholders' equity	5,910	6,399	6,965	7,522	8,202
let working capital	(276)	(339)	(340)	(332)	(390)
ivested capital	3,382	3,402	3,743	3,795	3,786
Includes convertibles and preferred stock which is bein					,
er share (THB)					
ook value per share	6.46	6.92	7 55	Q 10	8.88
ook value per snare angible book value per share	6.46	6.92 6.92	7.55 7.55	8.19 8.19	8.88 8.88
č	0.40	0.92	60.1	0.19	0.00
inancial strength	(0==)		(10.0)		
let debt/equity (%)	(37.3)	(41.2)	(40.4)	(44.2)	(48.7
let debt/total assets (%)	(32.0)	(35.0)	(34.4)	(37.8)	(41.5
current ratio (x)	3.6	3.5	3.5	3.9	4.(
F interest cover (x)	(13.2)	(11.8)	(9.8)	(17.0)	(17.0)
aluation	2023	2024	2025E	2026E	2027E
ecurring P/E (x) *	31.1	24.4	21.3	19.2	17.3
ecurring P/E @ target price (x) *	42.3	33.1	28.9	26.1	23.0
eported P/E (x)	31.1	24.4	21.3	19.2	17.3
ividend yield (%)	1.4	1.8	2.3	2.6	2.9
rice/book (x)	3.4	3.2	2.9	2.0	2.5
rice/tangible book (x)	3.4	3.2	2.9	2.7	2.5
V/EBITDA (x) **	16.2	13.6	11.8	10.2	8.9
V/EBITDA @ target price (x) **	22.6	19.2	16.7	14.5	12.9
V/invested capital (x)	4.6	4.4	4.0	3.8	3.7

Sources: Praram 9 Hospital; FSSIA estimates



Praram 9 Hospital PCL (PR9 TB)



54.08 /100

Exhibit 2: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star\star\star\star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA		Domestic ratings					Bl	oomberg						
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
всн	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	-	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	—	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	-	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	_	20.68	20.68
Governance disclosure score	_	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	0	0
GHG scope 2 location-based	_	4	6
GHG Scope 3	_	0	5
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	_	7	13
Renewable energy use	_	_	_
Electricity used	_	_	_
Fuel used - natural gas	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	No	Yes	Yes
Hazardous waste	—	_	_
Total waste	—	_	_
Waste recycled	—	_	_
Waste sent to landfills	—	—	_
Environmental supply chain management	No	No	No
Water policy	No	Yes	Yes
Water consumption	—	60	151
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	No	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	No	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	—	—	—
Pct disabled in workforce	—	—	—
Business ethics policy	No	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	No	Yes	Yes
Lost time incident rate - employees	—	—	_
Total recordable incident rate - employees	—	1	0
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	2,083	1,987	2,011
Employee turnover pct	—	11	13
Total hours spent by firm - employee training	14,566	13,462	66,852
Social supply chain management	No	No	No
Governance			
Board size	10	10	9
No. of independent directors (ID)	4	7	6
No. of women on board	2	2	2
No. of non-executive directors on board	7	7	6
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	7	7	7
Board meeting attendance pct	97	100	89
Board duration (years)	3	3	3
Director share ownership guidelines	No	No	No
Age of the youngest director	56	56	57
Age of the oldest director	72	73	74
No. of executives / company managers	7	5	5
No. of female executives	2	0	C
Executive share ownership guidelines	No	No	No
Size of audit committee	3	3	3
No. of ID on audit committee	3	3	3
Audit committee meetings	4	4	4
Audit meeting attendance %	100	100	100
Size of compensation committee	3	3	3
No. of ID on compensation committee	3	2	3
No. of compensation committee meetings	2	2	2
Compensation meeting attendance %	83	100	100
Size of nomination committee	3	3	3
No. of nomination committee meetings	2	2	2
Nomination meeting attendance %	83	100	100
Sustainability governance			
Verification type	No	No	No

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	IY			Rating					
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the anr Only the top inclusion.	The DJSI World applies a transparent, rules-based component selection ocess based on the companies' Total Sustainability Scores resulting om the annual S&P Global Corporate Sustainability Assessment (CSA). Inly the top-ranked companies within each industry are selected for clusion.							an S&P Globa of the highest JSI indices are	
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing bu Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders ome key disq ependent direc related to CG	onsibility in Environmenta ransparency in Governar e preemptive criteria, with he board members and e s, and combined holding ualifying criteria include: ctors and free float violati S, social & environmental earnings in red for > 3 ye	nce, updated annually. In two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below ion; 3) executives' impacts; 4) equity in	 minimum of 50% for each indicator, unless the company is a part of D during the assessment year. The scoring will be fairly weighted again nature of the relevant industry and materiality. <u>SETESG Index</u> is extended from the SET ESG Ratings companies w 1) market capitalization > THB5b (~USD150b); 2) free float >20%; an liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% 					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (SE	the Thai IOD,	th in sustainable develop with support from the St Its are from the perspecti ns.	ock Exchange of	Good (80-89), 3 and not rated for equitable treat	3 for Good (70 or scores below nent of shareh (5%); 4) disclo	ories: 5 for Excell -79), 2 for Fair (6 w 50. Weightings olders (weight 2 sure & transpare	0-69), 1 for P include: 1) th 5% combined	ass (60-69), e rights; 2) and i; 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), <i>circulation of s</i> <i>exercised. The</i> <i>and verifiability</i>	e incorporated and sufficientl e CG compor r AGM proced and after the ufficient informa- e second assess y; and 3) openno	which shareholders' right d into business operation ly disclosed. All form imp nents to be evaluated an dures before the meeting meeting (10%). (The first ation for voting; and 2) facilita ses 1) the ease of attending r less for Q&A. The third involv ues, resolutions and voting re	as and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be neetings; 2) transparency es the meeting minutes that			four categories: (80-89), and not			
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies d Declaration of Certification, ii managers and	nt of key contr eciding to becorr Intent to kick of ncluding risk ass employees, est	Checklist include corrupt trols, and the monitoring a is good for three years. me a CAC certified member s ff an 18-month deadline to su sessment, in place of policy a stablishment of whistleblowing all stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for and control, training of	passed Checkli	st will move fo se members a	ed by a committe r granting certific re twelve highly r chievements.	ation by the C	CAC Council	
<u>Morningstar</u> Sustainalytics	based on an risk is unma regulatory filing	assessment naged. Source gs, news and ot	risk rating provides an over of how much of a compa as to be reviewed include corp ther media, NGO reports/web	ny's exposure to ESG porate publications and psites, multi-sector	more risk is un	managed, the	score is the sum higher ESG risk i	s scored.	d risk. The Severe	
		ompany feedbac uality & peer rev		controversies, issuer feedback on draft ESG NEGL Low Medium High So 0-10 10-20 20-30 30-40						
ESG Book	positioned to the principle helps explain over-weighti	o outperform o of financial m n future risk-a	sustainable companies the over the long term. The m nateriality including inform adjusted performance. Ma vith higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	scores using m	ateriality-base	ated as a weighte d weights. The s dicating better pe	core is scaled		
MSCI				anagement of financially their exposure to ESG ris					ethodology to	
	AAA	8.571-10.00		La salta a ita industra in an			den en den en enterette			
	AA	7.143-8.57	0 Leader:	leading its industry in m	anaging the most si	gnilicant ESG hs	sks and opportunitie	5		
	Α	5.714-7.142	2	a mixed or unexception	al track record of m	proging the mean	t oignificant ESC rig	ke and apportur	vitico rolativo to	
	BBB	4.286-5.71	-	industry peers		anaging the mos	a significant LOG ha	ks and opportui		
	BB B	2.857-4.28								
	CCC	1.429-2.85 0.000-1.42	Laggard:	lagging its industry base	ed on its high expos	ure and failure to	o manage significan	t ESG risks		
Moody's ESG solutions	Moody's ass believes that	esses the deg t a company i	gree to which companies	take into account ESG on to its business model and medium to long term.						
<u>Refinitiv ESG</u> rating	based on pu	blicly availabl	le and auditable data. Th	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performan	ce and insufficier	nt degree of ti		
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, opp	oortunities, an	d impacts	
	ESG Score				•	nental, Social				
Bloomberg		ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.								

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 22.10	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 18-Feb-2025 unless otherwise stated.



RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.